Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
Alpha Tau Medical (NASDAQ: DRTS) has successfully closed a $36.9 million registered direct offering with Oramed Pharmaceuticals. The deal involves the sale of 14,110,121 ordinary shares at $2.612 per share to an Oramed affiliate.
The company plans to use the proceeds for general corporate purposes, including R&D for product candidates, manufacturing expansion, and potential commercialization efforts. Additionally, an Oramed affiliate will provide strategic services in investor and public relations over three years in exchange for payments and warrants for additional Alpha Tau shares.
The investment aligns with Alpha Tau's current growth phase, marked by four active U.S. trial approvals, expansion into multiple internal organ applications, manufacturing scale-up, and ongoing commercial preparations for their Alpha DaRT® alpha-radiation cancer therapy.
Alpha Tau Medical (NASDAQ: DRTS) ha concluso con successo un'offerta diretta registrata da 36,9 milioni di dollari con Oramed Pharmaceuticals. L'accordo prevede la vendita di 14.110.121 azioni ordinarie a 2,612 dollari per azione a una società affiliata di Oramed.
La società intende utilizzare i proventi per scopi aziendali generali, inclusi ricerca e sviluppo di candidati prodotto, espansione della produzione e possibili attività di commercializzazione. Inoltre, una società affiliata di Oramed fornirà servizi strategici nelle relazioni con investitori e pubbliche relazioni per tre anni in cambio di pagamenti e warrant per ulteriori azioni Alpha Tau.
L'investimento è in linea con la fase di crescita attuale di Alpha Tau, caratterizzata da quattro approvazioni attive di trial negli USA, espansione in diverse applicazioni per organi interni, aumento della capacità produttiva e preparativi commerciali in corso per la loro terapia oncologica a radiazione alfa Alpha DaRT®.
Alpha Tau Medical (NASDAQ: DRTS) ha cerrado con éxito una oferta directa registrada de 36,9 millones de dólares con Oramed Pharmaceuticals. El acuerdo implica la venta de 14.110.121 acciones ordinarias a 2,612 dólares por acción a una afiliada de Oramed.
La compañía planea usar los fondos para fines corporativos generales, incluyendo I+D para candidatos a productos, expansión de la fabricación y posibles esfuerzos de comercialización. Además, una afiliada de Oramed proporcionará servicios estratégicos en relaciones con inversores y públicas durante tres años a cambio de pagos y warrants para acciones adicionales de Alpha Tau.
La inversión está alineada con la fase de crecimiento actual de Alpha Tau, marcada por cuatro aprobaciones activas de ensayos en EE. UU., expansión en múltiples aplicaciones para órganos internos, aumento de la producción y preparativos comerciales en curso para su terapia contra el cáncer con radiación alfa Alpha DaRT®.
Alpha Tau Medical(나스닥: DRTS)는 Oramed Pharmaceuticals와 함께 3,690만 달러 규모의 등록 직접 공모를 성공적으로 마무리했습니다. 이번 거래는 Oramed 계열사에 보통주 14,110,121주를 주당 2.612달러에 판매하는 내용입니다.
회사는 이 자금을 제품 후보에 대한 연구개발, 제조 확장, 잠재적 상업화 활동 등 일반 기업 목적에 사용할 계획입니다. 또한 Oramed 계열사는 3년간 투자자 및 대외 관계에 관한 전략적 서비스를 제공하며, 이에 대한 대가로 Alpha Tau 추가 주식에 대한 지급 및 워런트를 받습니다.
이번 투자는 미국 내 4건의 활성 임상 승인, 다수의 내부 장기 적용 확대, 제조 규모 확대, 그리고 Alpha DaRT® 알파 방사선 암 치료제에 대한 상업 준비 진행 등 Alpha Tau의 현재 성장 단계와 부합합니다.
Alpha Tau Medical (NASDAQ : DRTS) a clôturé avec succès une offre directe enregistrée de 36,9 millions de dollars avec Oramed Pharmaceuticals. L'accord porte sur la vente de 14 110 121 actions ordinaires à 2,612 dollars par action à une filiale d'Oramed.
La société prévoit d'utiliser les fonds pour des besoins généraux d'entreprise, y compris la R&D pour les candidats produits, l'expansion de la production et d'éventuelles actions de commercialisation. De plus, une filiale d'Oramed fournira des services stratégiques en relations investisseurs et relations publiques pendant trois ans en échange de paiements et de bons de souscription d'actions supplémentaires d'Alpha Tau.
L'investissement s'inscrit dans la phase de croissance actuelle d'Alpha Tau, marquée par quatre approbations actives d'essais aux États-Unis, une expansion vers plusieurs applications d'organes internes, une montée en puissance de la production et des préparatifs commerciaux en cours pour leur thérapie anticancéreuse par rayonnement alpha Alpha DaRT®.
Alpha Tau Medical (NASDAQ: DRTS) hat erfolgreich ein registriertes Direktangebot über 36,9 Millionen US-Dollar mit Oramed Pharmaceuticals abgeschlossen. Der Deal umfasst den Verkauf von 14.110.121 Stammaktien zu je 2,612 US-Dollar an eine Tochtergesellschaft von Oramed.
Das Unternehmen plant, die Erlöse für allgemeine Unternehmenszwecke zu verwenden, darunter Forschung und Entwicklung von Produktkandidaten, Ausbau der Produktion und mögliche Kommerzialisierungsaktivitäten. Zusätzlich wird eine Oramed-Tochtergesellschaft über drei Jahre strategische Dienstleistungen im Bereich Investor Relations und Öffentlichkeitsarbeit erbringen, wofür sie Zahlungen und Warrants für weitere Alpha Tau-Aktien erhält.
Die Investition passt zur aktuellen Wachstumsphase von Alpha Tau, die durch vier aktive US-Zulassungen für Studien, die Erweiterung auf mehrere innere Organanwendungen, Produktionsausbau und laufende kommerzielle Vorbereitungen für ihre Alpha DaRT® Alphastrahlen-Krebstherapie gekennzeichnet ist.
- Secured substantial funding of $36.9M through registered direct offering
- Strategic partnership with Oramed for investor and public relations services
- Four active U.S. trial approvals indicating clinical progress
- Expansion into multiple internal organ applications showing technology versatility
- Manufacturing capacity scaling up for commercial preparation
- Share dilution from issuance of 14,110,121 new ordinary shares
- Additional dilution potential from future warrant exercises
- Ongoing expenses for strategic services payments to Oramed
Insights
Alpha Tau's $36.9M investment from Oramed strengthens financial position, funds clinical pipeline advancement, and adds strategic IR/PR support.
Alpha Tau Medical has secured a significant
Beyond just capital, the transaction establishes a strategic partnership where Oramed will provide investor relations and public relations services over the next three years, receiving payment and warrants for additional Alpha Tau shares. This multi-faceted relationship adds expertise that could enhance Alpha Tau's market visibility while executing their growth strategy.
The financing strengthens Alpha Tau's balance sheet without adding debt, providing operational runway to support their expanding clinical program and commercial preparations. For a company advancing multiple clinical trials simultaneously, this capital certainty is particularly valuable, removing near-term financing pressure and allowing management to focus on execution across their development pipeline and manufacturing scale-up initiatives.
Alpha Tau's innovative alpha-radiation cancer therapy gains momentum with strategic funding to expand clinical applications and manufacturing capabilities.
Alpha Tau's Alpha DaRT technology represents an innovative approach to cancer treatment utilizing alpha radiation - which offers uniquely high energy over very short distances, potentially allowing precise tumor targeting while minimizing damage to surrounding healthy tissues. The company's expansion into multiple internal organ applications signals an important clinical development beyond their initial focus, suggesting broader therapeutic potential for their platform technology.
The company's progress with four active U.S. trial approvals demonstrates advancing regulatory momentum and clinical validation across multiple indications. This multi-pronged clinical strategy reduces risk by diversifying across different cancer applications rather than depending on a single indication.
Particularly noteworthy is Alpha Tau's parallel investment in manufacturing scale-up alongside clinical development, indicating forward-looking preparation for potential commercialization. For radiation-based therapies, manufacturing infrastructure involves specialized facilities with stringent quality controls and regulatory requirements. The
This financing and strategic partnership with Oramed strengthens Alpha Tau's position to continue advancing their radiation-based cancer therapy platform through clinical development toward potential market readiness.
Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active U.S. trial approvals, expansion into multiple internal organ applications, scaling up of manufacturing capabilities, and commercial preparations underway
JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that it has successfully closed a registered direct offering (the “offering”) whereby an affiliate of Oramed Pharmaceuticals Inc. (“Oramed”) (Nasdaq: ORMP) (TASE: ORMP) purchased 14,110,121 of Alpha Tau’s ordinary shares, no par value, at a purchase price of
The total gross proceeds of the offering were approximately
In addition, the parties have entered into an agreement whereby an affiliate of Oramed will provide Alpha Tau with certain strategic services (investor relations and public relations) over the next three years in exchange for payments from Alpha Tau as well warrants to purchase additional Alpha Tau shares.
Alpha Tau CEO Uzi Sofer commented, “We are delighted to welcome Oramed as a strategic partner and to leverage their extensive expertise in navigating diverse capital markets channels. This investment comes at the perfect time for Alpha Tau given the rapid expansion of our business activities, including four parallel trial approvals in the U.S., expansion into trials in multiple internal organs, and continued expansion of our manufacturing capacity and pre-commercial preparations. We look forward to a long and fruitful relationship with Oramed.”
Oramed CEO Nadav Kidron added, “We are incredibly excited about this alliance with Alpha Tau. We have tremendous conviction in the strength of the Alpha DaRT technology and the Alpha Tau management team. We anticipate significant advancements and milestone achievements as they execute their clinical and commercial roadmap.”
A registration statement on Form F-3 relating to the securities to be sold in the registered direct offering has been filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on April 13, 2023. This registered direct offering was made only by means of a prospectus. A copy of the prospectus supplement and the accompanying prospectus relating to this offering was filed with the SEC and may be obtained for free by visiting EDGAR on the SEC's website at www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT® for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. The Company’s novel Protein Oral Delivery (POD™) technology is designed to protect drug integrity and increase absorption. Oramed has offices in the United States and Israel.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including "anticipate," "being," "will," "plan," "may," "continue," and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Alpha Tau's current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) the completion of the offering and the intended use of the proceeds (ii) Alpha Tau's ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (iii) Alpha Tau's limited operating history; (iv) Alpha Tau's incurrence of significant losses to date; (v) Alpha Tau's need for additional funding and ability to raise capital when needed; (vi) Alpha Tau's limited experience in medical device discovery and development; (vii) Alpha Tau's dependence on the success and commercialization of the Alpha DaRT technology; (viii) the failure of preliminary data from Alpha Tau's clinical studies to predict final study results; (ix) failure of Alpha Tau's early clinical studies or preclinical studies to predict future clinical studies; (x) Alpha Tau's ability to enroll patients in its clinical trials; (xi) undesirable side effects caused by Alpha Tau's Alpha DaRT technology or any future products or product candidates; (xii) Alpha Tau's exposure to patent infringement lawsuits; (xiii) Alpha Tau's ability to comply with the extensive regulations applicable to it; (xiv) the ability to meet Nasdaq's listing standards; (xv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption "Risk Factors" in Alpha Tau's annual report filed on form 20-F with the SEC on March 12, 2025, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau's views as of any date subsequent to the date of this press release.
Investor Relations Contact:
IR@alphatau.com
FAQ
How much did Alpha Tau Medical (DRTS) raise in their April 2025 registered direct offering?
What is the strategic partnership between Alpha Tau (DRTS) and Oramed Pharmaceuticals?
How will Alpha Tau (DRTS) use the proceeds from the $36.9M offering?
What are the current growth initiatives for Alpha Tau's (DRTS) Alpha DaRT technology?
